Global Buccal Drug Delivery Systems Market Size By Type (Sublingual Films, Tablets), By Application (Hospitals, Clinics), By Region, And Segment Forecasts, 2023 to 2032

lobal Buccal Drug Delivery Systems Market Report Description

The Global Buccal Drug Delivery Systems Market was valued at USD 4.6 billion in 2023 and is projected to reach USD 8.1 billion by 2031, growing at a CAGR of 7.4% during the forecast period (2023–2031).

Buccal drug delivery systems provide a non-invasive route for systemic drug administration via the buccal mucosa. The rising prevalence of chronic diseases, growing demand for patient-compliant drug delivery methods, and the ability to bypass first-pass hepatic metabolism are key factors driving market growth. Additionally, advancements in mucoadhesive technologies and novel drug formulations are expanding therapeutic applications, thereby accelerating adoption.

Drivers

1. Rising Prevalence of Chronic and Infectious Diseases

The growing incidence of chronic diseases like cardiovascular conditions, cancer, and diabetes is increasing the need for efficient, sustained drug delivery. Buccal delivery systems provide controlled drug release and improved patient compliance, which is critical for long-term therapies.

2. Advancements in Drug Delivery Technology

Innovations in mucoadhesive polymers, nanocarrier-based buccal patches, and bioadhesive films are improving drug stability and bioavailability. These technological developments are enhancing the market potential of buccal systems for diverse therapeutic applications.

3. Growing Demand for Non-Invasive Drug Delivery Methods

Buccal systems offer painless administration compared to injections, making them favorable for pediatric, geriatric, and needle-phobic patients. This growing preference for non-invasive delivery supports market growth.

Restraints

1. Limited Drug Absorption for Certain Molecules

The buccal mucosa has limited surface area and enzymatic activity that can restrict the absorption of certain large or hydrophilic drugs, limiting the therapeutic scope of buccal delivery systems.

2. High Development and Formulation Costs

Developing stable, bioadhesive formulations with optimal drug release profiles requires significant R&D investments, which can hinder market penetration, especially for smaller pharmaceutical firms.

Opportunities

1. Expansion into Biologics and Vaccines

The development of buccal delivery systems for biologics, peptides, and vaccines presents significant growth opportunities. Advances in permeation enhancers and nanotechnology are making this possible.

2. Increasing Adoption in Emerging Markets

Rising healthcare awareness, expanding pharmaceutical infrastructure, and growing demand for patient-centric therapies in Asia-Pacific and Latin America are creating lucrative market opportunities.

Market by System Type Insights

Mucoadhesive Buccal Tablets and Films accounted for the largest share in 2023, driven by ease of administration and sustained drug release capabilities.

Buccal Sprays and Solutions are expected to grow fastest due to their rapid onset of action and convenience, particularly in emergency therapies like pain management.

Market by End-Use Insights

Hospitals and Specialty Clinics dominated the market in 2023 as primary end-users, owing to higher adoption rates for advanced drug delivery systems.

Retail Pharmacies and Homecare Settings are expected to witness substantial growth due to the rising trend of self-administration and patient-centric therapies.

Market by Regional Insights

North America held the largest market share in 2023 due to high healthcare expenditure, rapid adoption of innovative drug delivery technologies, and the presence of key pharmaceutical players.

Asia-Pacific is projected to be the fastest-growing region, driven by expanding healthcare infrastructure, increasing generic drug manufacturing, and growing chronic disease prevalence in countries like China and India.

Europe also holds a significant share due to strong regulatory frameworks supporting advanced drug delivery methods.

Competitive Scenario

Key players in the Global Buccal Drug Delivery Systems Market include Teva Pharmaceutical Industries Ltd., Pfizer Inc., Indivior PLC, BioDelivery Sciences International, Aquestive Therapeutics, ZIM Laboratories, and Luye Pharma Group.

These companies are focusing on R&D investments, strategic partnerships, and regulatory approvals to expand their buccal drug delivery portfolios.

2023: Aquestive Therapeutics launched a next-generation buccal film for opioid dependence therapy.

2024: Teva Pharmaceuticals entered a collaboration to develop peptide-based buccal formulations targeting chronic pain management.

2025: Pfizer expanded its production capacity for mucoadhesive buccal tablets in Europe to meet growing demand.

Scope of Work – Global Buccal Drug Delivery Systems Market

Key Market Developments

July 2023: Aquestive Therapeutics introduced a novel buccal film for epilepsy management with enhanced bioavailability.

March 2024: Indivior PLC secured FDA approval for its new buccal formulation for opioid use disorder treatment.

January 2025: ZIM Laboratories partnered with a biotech firm to develop buccal vaccines for infectious diseases.

FAQs

1) What is the current market size of the Global Buccal Drug Delivery Systems Market?

The market was valued at USD 4.6 billion in 2023.

2) What is the major growth driver of the Global Buccal Drug Delivery Systems Market?

The major growth drivers include the rising prevalence of chronic diseases, advancements in mucoadhesive technologies, and growing demand for patient-compliant non-invasive therapies.

3) Which is the largest region during the forecast period in the Global Buccal Drug Delivery Systems Market?

North America is expected to remain the largest region, while Asia-Pacific will witness the fastest growth.

4) Which segment accounted for the largest market share in the Global Buccal Drug Delivery Systems Market?

The Mucoadhesive Tablets & Films segment accounted for the largest market share in 2023.

5) Who are the key market players in the Global Buccal Drug Delivery Systems Market?

Key players include Teva Pharmaceutical Industries Ltd., Pfizer Inc., Indivior PLC, Aquestive Therapeutics, BioDelivery Sciences International, and ZIM Laboratories.

Would you like me to create similar structured reports for multiple drug delivery markets or generate a visual infographic summarizing this market?